NeuroPace(NASDAQ) NPCE

Market Cap$521.63M

Since IPO (2021)-39%

5 Year-27%

1 Year+70%

1 Month-7%

$15.31

+0.07%

+0.01Today

NeuroPace last closing stock price
Metric	Price	Date
Last close	USD 15.30	2026-07-27

NeuroPace stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.86%	USD 15.75	2026-07-20
1 month	-7.1%	USD 16.47	2026-06-26
3 month	-9.41%	USD 16.89	2026-04-28
Year to date	-0.91%	USD 15.44	2025-12-31
1 year	+70.38%	USD 8.98	2025-07-25
3 year	+274.08%	USD 4.09	2023-07-28
5 year	-27.14%	USD 21.00	2021-07-28
Since inception	-38.7%	USD 24.96	2021-04-22

NeuroPace Financials at a Glance

Market Cap

$521.63M

Revenue (TTM)

$99.53M

Net Income (TTM)

-$21.57M

EPS (TTM)

-$0.65

P/E Ratio

-23.58

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$15.31

Volume

11,920

Open

$15.70

Price

$15.31

Volume

11,920

Open

$15.70

Previous Close

$15.31

Daily Range

$15.21 - $15.82

52-Week Range

$7.56 - $19.60

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$15.31

Volume

11,920

Open

$15.70

Previous Close

$15.31

Daily Range

$15.21 - $15.82

52-Week Range

$7.56 - $19.60

Estimated Earnings Date

Aug 11, 2026

NPCE News

Two people participating in a telehealth session

NPCE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeuroPace

NeuroPace makes a smart device to stop seizures. It helps people whose epilepsy medicine does not work. The device monitors brain activity and gives treatment.

The Tools for Seizure Control

RNS Neurostimulator: Battery-powered device placed under the scalp to sense and stop seizures; acts as the primary revenue source.
Leads and Electrodes: Tiny wires that detect abnormal brain patterns and deliver real-time electrical pulses to the seizure source.
Patient Remote Monitor: Portable system used by patients to send recorded brain data to doctors for remote review.
Physician Tablet: Clinical tool used for viewing brain activity and adjusting the detection and stimulation settings of the device.
Data Management System: Secure online database that stores millions of brain activity records to help doctors make treatment decisions.

Where is the Business Expanding?

Filed a request with the FDA in December 2025 to treat idiopathic generalized epilepsy, which involves seizures that affect the entire brain.
Collaborated with Rapport Therapeutics, Inc. in 2023 to use brain data for evaluating new pharmaceutical products in clinical trials.
Entered a distribution agreement in late 2025 with an Israeli distributor to begin limited sales of the RNS System in Israel.
Ended a distribution partnership for stereo EEG products with DIXI Medical USA Corp. in late 2025 to focus on core products.

Using Data to Improve Lives

The company owns a unique database of over 22 million brain activity records collected from more than 8,000 patients. This data allow doctors to monitor patients remotely and adjust treatment based on objective brain wave patterns rather than patient memory.

Financial Performance in 2025

Revenue reached $26.6 million in Q4 2025, up 23.9% from $21.5 million in Q4 2024.
Gross profit was $20.6 million in Q4 2025, up 27.1% from $16.2 million in the previous year.
Net income was -$2.7 million in Q4 2025, which narrowed and improved from -$5.2 million in Q4 2024.
Free cash flow turned positive at $409,000 in Q4 2025, improved from -$4.8 million in Q4 2024.

Bottom Line

NeuroPace has transitioned from a research firm into a commercial healthcare provider using large-scale brain data to treat complex neurological disorders. Its focus on personalized, responsive therapy supports its expansion into new types of epilepsy and international markets.

AI Generated • May 5, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

209

CEO

Joel D. Becker, MBA

Website

www.neuropace.com

Headquarters

Mountain View, CA 94043, US

NPCE Financials

Key Financial Metrics (TTM)

Gross Margin

78.29%

Operating Margin

-16.84%

Net Income Margin

-21.67%

Return on Equity

-120.74%

Return on Capital

-18.18%

Return on Assets

-21.81%

Earnings Yield

-4.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$521.63M

Shares Outstanding

34.09M

Volume

11.92K

Avg. Volume

188.24K

Financials (TTM)

Gross Profit

$77.93M

Operating Income

-$16.76M

EBITDA

-$13.84M

Operating Cash Flow

-$9.42M

Capital Expenditure

-$412.00K

Free Cash Flow

-$9.84M

Cash & ST Invst.

$53.98M

Total Debt

$70.46M

NeuroPace Performance Analysis

NeuroPace annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 45,520,000	0.7%
2023	2023-12-31	USD 65,421,000	43.7%
2024	2024-12-31	USD 79,906,000	22.1%
2025	2025-12-31	USD 99,986,000	25.1%

NeuroPace sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	4.4%
Q3	2025-09-30	16.3%
Q4	2025-12-31	-2.8%
Q1	2026-03-31	-17.0%

NeuroPace annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.91	29.7%
2023	2023-12-31	USD -1.27	-33.4%
2024	2024-12-31	USD -0.93	-26.9%
2025	2025-12-31	USD -0.66	-29.6%

NeuroPace sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-23.8%
Q3	2025-09-30	57.7%
Q4	2025-12-31	25.7%
Q1	2026-03-31	-144.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$22.07M

-2.0%

Gross Profit

$18.05M

+4.1%

Gross Margin

81.78%

N/A

Market Cap

$521.63M

N/A

Market Cap/Employee

$2.37M

N/A

Employees

220

N/A

Net Income

-$6.69M

-1.5%

EBITDA

-$4.66M

-17.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$53.98M

-18.5%

Total Debt

$70.46M

-3.7%

Accounts Receivable

$14.79M

-4.2%

Inventory

$16.69M

+22.9%

Long Term Debt

$68.28M

-4.1%

Short Term Debt

$2.19M

+13.7%

Return on Assets

-21.81%

N/A

Return on Invested Capital

-20.26%

N/A

Free Cash Flow

-$6.02M

+20.0%

Operating Cash Flow

-$5.90M

+21.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CERSCerus Corporation

CERSCerus Corporation$2.92-4.89%

BWAYBrainsWay Ltd.

BWAYBrainsWay Ltd.$15.49-1.71%

DCTHDelcath Systems, Inc.

DCTHDelcath Systems, Inc.$11.55-3.27%

MASS908 Devices Inc.

MASS908 Devices Inc.$7.03-1.40%

SGHTSight Sciences, Inc.

SGHTSight Sciences, Inc.$5.30+3.52%

RXSTRxSight, Inc.

RXSTRxSight, Inc.$6.05+7.27%

SENSSenseonics Holdings, Inc.

SENSSenseonics Holdings, Inc.$4.91-2.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.22-0.01%

NOKNokia

NOKNokia$8.93-0.03%

JBLUJetBlue Airways

JBLUJetBlue Airways$6.00+0.10%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.15-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.74-0.01%

FFord Motor Company

FFord Motor Company$14.96+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.56-0.03%

Questions About NPCE

What is the current price of NeuroPace?

NeuroPace is trading at $15.31 per share.

What is the 52-week range for NeuroPace?

Over the past 52 weeks, NeuroPace has traded between $7.56 and $19.60.

How much debt does NeuroPace have?

As of the most recent reporting period, NeuroPace reported total debt of $70.46M.

How much cash does NeuroPace have on hand?

NeuroPace reported $14.78M in cash and cash equivalents in its most recent financial results.

What is NeuroPace’s dividend yield?

NeuroPace does not currently have a dividend yield.

NeuroPace(NASDAQ) NPCE

NeuroPace Financials at a Glance

NPCE News

Why NeuroPace Stock Was Inching Higher on Wednesday

NeuroPace Revenue Jumps 22 Percent in Q2

NeuroPace Reports Record Q2 Revenue

Could This Recently IPOed Medical Device Maker Make You Rich?

NPCE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NeuroPace

The Tools for Seizure Control

Where is the Business Expanding?

Using Data to Improve Lives

Financial Performance in 2025

Bottom Line

NPCE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NeuroPace Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NPCE

What is the current price of NeuroPace?

What is the 52-week range for NeuroPace?

How much debt does NeuroPace have?

How much cash does NeuroPace have on hand?

What is NeuroPace’s dividend yield?

Premium Investing Services